No Data
No Data
No Data
No Data
No Data
Declining Stock and Solid Fundamentals: Is The Market Wrong About Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439)?
Guizhou Sanli PharmaceuticalLtd (SHSE:603439) has had a rough three months with its share price down 22%. But if you pay close attention, you might gather that its strong financials could mean that
Simply Wall StApr 16 18:04 ET
Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Shares Could Be 34% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Guizhou Sanli PharmaceuticalLtd fair value estimate is CN¥26.33 Guizhou Sanli PharmaceuticalLtd's CN¥17.31 share price signals that it might
Simply Wall StMar 15 19:50 ET
Does Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Simply Wall StFeb 26 20:05 ET
Why Investors Shouldn't Be Surprised By Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) 30% Share Price Plunge
Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performanc
Simply Wall StFeb 3 19:30 ET
Guizhou Sanli (603439.SH): Controlling shareholders and their concerted actors have already reduced their holdings
Gelonghui, January 29丨Guizhou Sanli (603439.SH) announced that as of the disclosure date of this announcement, the reduction period had expired, and Mr. Zhang Hai had not reduced their holdings. Ms. Wang Huiying and Ms. Ling Zongrong reduced their holdings by 4.193,500 shares through centralized bidding transactions, accounting for 1.0231% of the company's total share capital; Ms. Wang Huiying reduced her holdings by 7.928,800 shares through bulk transactions, accounting for 1.9345% of the company's total share capital. The controlling shareholders and their concerted actors reduced their holdings by a total of 12.1223 million shares, accounting for 2.9576% of the company's total share capital.
Gelonghui FinanceJan 29 03:25 ET
Guizhou Sanli (603439.SH): There are currently no plans to raise prices in the short term
Gelonghui, January 19丨Guizhou Sanli (603439.SH) recently said during a survey receiving institutional investors that the rise in Chinese herbal medicines mainly began in the second half of '22, and all kinds of traditional Chinese medicine raw materials have increased to varying degrees. Currently, judging from our subsidiaries and major varieties, there is little impact on Sanli. Chinese Medicine and Dechangxiang have increased slightly in terms of costs due to their large variety of varieties and the need for more Chinese herbal medicines. Since the company and its subsidiaries are still developing various terminal market layouts, there are no plans to raise prices in the short term.
Gelonghui FinanceJan 18 19:20 ET
No Data
No Data